Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. - Wikidata - wikimedia - TriplyDB

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

http://www.wikidata.org/entity/Q37019841

about

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Inherited susceptibility for aggressive prostate cancer Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Novel non-AR therapeutic targets in castrate resistant prostate cancer Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.Urological cancer related to familial syndromes.Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers Current condition of genetic medicine for hereditary breast cancer.Mutations in BRCA2 and taxane resistance in prostate cancer BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data.Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.Screening for familial and hereditary prostate cancer.The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).The role of BRCA1 and BRCA2 in prostate cancer.Genetics and genomics of prostate cancer.Somatic alterations contributing to metastasis of a castration-resistant prostate cancer Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Familial prostate cancer: the damage done and lessons learnt.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.The clinical development of inhibitors of poly(ADP-ribose) polymerase.Prostate cancer: germline prediction for a commonly variable malignancy.Molecular biomarkers to guide precision medicine in localized prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond.BRCA1 and p53 regulate critical prostate cancer pathways.

P2860

Q24302687-A483CF39-79EF-4CD7-A2F9-9F5C66DAD193 Q27001297-6EDA5541-D8B1-45DB-978C-3D899F974FB1 Q27852185-7D797696-2595-4FC4-920C-0B9D4BE24F8A Q28073673-ABF30395-A762-4142-838E-FD728DC7D82E Q28383663-828C6AC7-0D45-4067-92F1-68F2A8C98D6C Q30361333-382C85C5-B8BF-4EF8-A060-B2E5E8D9B3AB Q30597063-96548FF8-9904-459C-9F7F-AC48D636FC64 Q33692605-B0867505-E08D-4232-89AB-E537517F84BF Q33796352-43B3DBB1-5CB2-4DCF-8F04-13A3588CD649 Q33858408-FFF67BF4-3189-463D-971D-813121E5657F Q33870601-A559A482-6C34-47D8-AECD-916898030D6B Q33881971-76FF4EC4-7C16-4069-A8CE-3ED1BDEEB15A Q33927384-51EDEEE6-601C-4436-867F-3AB321BBA397 Q34481443-38A9FA37-99AB-4185-BB7A-410AB970FB69 Q34612586-704F4B60-017F-46F5-92CC-47380775C460 Q34838226-F67CA37A-F709-4280-8E38-7DD4408FAB00 Q35018746-2D90807A-AEB7-49B2-A4ED-B9834F858046 Q35527158-01DEDC6D-55C7-4564-A3A6-AE017D8AB90D Q35861576-8BBF7E0E-4B59-4217-AD59-E13A1B9AAA55 Q35906685-E99AD24B-48C9-4D8E-8A6D-B5E762C0BA5E Q35907075-ECB53319-C46B-4611-9A89-AA82D93ADC8A Q36332690-5122BDA2-8861-4CFF-AC67-735654CB9A7D Q36347042-72BB6431-9EB8-4CB5-AB9C-AA74CF302210 Q36621757-D593C803-767D-4438-97FC-BC7F6969AE75 Q36746831-1483CE8E-A7D3-426B-805D-9A72CFB6977B Q37037789-49430B3F-2ADB-45BA-AC1E-9EF8350CE10B Q37085413-1B2DEA44-86AB-4F35-BC64-12F18B69C90A Q37100131-AA35FDFA-FBBE-481D-9F4B-0F5642ADFF01 Q37179254-93D5BDF2-7C4A-4548-BA46-D5810019E8A7 Q37553869-25D8F170-37A3-4BE3-BB3A-4F2DBDC0ED8F Q37677557-CBADEEE7-8122-43BA-A1A1-8BE4F43B67FA Q37834139-585DD075-01AF-44F7-BA2B-0550115C5111 Q38043095-0E31C061-A32B-4B46-997C-5766AD366EA6 Q38668635-D520131D-2374-469F-97BE-D2A4693BEA26 Q38774228-7DDD6961-6DB2-4010-AF95-341C66963D2F Q38893354-D408C6DA-7DC0-42C3-A7A2-CC4D7070500C Q38983790-C65E1405-79B8-41A9-B4F7-BB0782DE923E Q39037653-376503CD-B143-4BBC-80F1-C0B16A9C9139 Q39141778-E58A8272-B8D7-4ADD-A32C-A831D6A258FF Q39152560-DF66ECF0-B07B-4D4E-A79F-7607CA325A53

P2860

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

http://www.wikidata.org/entity/Q37019841

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@en

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@nl

type

label

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@en

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@nl

prefLabel

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@en

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@nl

P1433

Q37019841-838909B7-69B5-40F5-9F22-F0FA112FD313

P1476

Q37019841-754E1663-AC55-4742-AA91-E808B6AAADD9

P2093

Q37019841-1F44288E-80E9-414D-B10B-65BA9D55D546

Q37019841-57000FC8-A2BA-4F9D-B6E0-36AAF528AAF5

Q37019841-74B258BC-3BE8-4D1E-9844-D6D5E7D288EF

Q37019841-764202E1-2BE3-49F2-8561-47088B216658

Q37019841-880523D3-562D-4085-B7A4-D3C42C54A635

Q37019841-9396E307-3E9D-4DA7-B64C-02F908098627

Q37019841-AF3001EF-8329-42BE-85EE-BFCB4CECF4E8

Q37019841-B2A6B1E2-0AAA-4B2E-967C-4C7C8BCF29A9

Q37019841-B6DD866B-5060-4EA1-95B7-79A8BD02FC73

Q37019841-BC5A0A9A-C761-431F-9249-6DC6B63F88BF

P2860

Q37019841-0047FB41-3027-445E-B31E-42B197BC18C7

Q37019841-11151F8F-8682-40CA-92DD-C1C9B5B07A2C

Q37019841-19F53312-7C08-47B2-A063-B8DBD78EC791

Q37019841-204F1FF7-C03D-4395-A513-5DAC904E01F7

Q37019841-27F8CA46-8355-4205-89A7-3B49CB35F95E

Q37019841-2F2177C5-446B-47BA-91F2-2B140B8A6A79

Q37019841-308BC03C-58FF-4A94-B410-5604B009F2BA

Q37019841-315105AC-BE3D-477B-8ED5-B9A32641BB75

Q37019841-41BD2643-5AE0-4542-92C3-68C5D2D01749

Q37019841-439D7972-972A-4808-ABD6-782E99BEB961

P304

Q37019841-14F2F231-4061-4988-8CE9-FC45F5225E14

P31

Q37019841-7E7C9961-2427-465E-B0C7-D8653B5BD332

P356

Q37019841-C7881E29-CE74-481C-99C1-D8F192E7BF66

P407

Q37019841-4E27301A-7A85-4AF8-8DC1-813A6BDAD483

P433

Q37019841-0B84CF91-B32E-478C-981E-8A76B6000FD2

P478

Q37019841-271705B1-8002-44EE-8B12-2F6F658E597A

P50

Q37019841-12EA8418-1EF6-4F61-AA34-BFD7FFA8B08E

Q37019841-539851EA-F119-40A6-8AC4-58CFD4982E49

Q37019841-8797476F-6622-4675-9868-E1F1D750BB2E

Q37019841-A2F851DB-7DF1-41EC-AD17-3CB31CCCD6A7

Q37019841-AABF7266-1E47-4153-9423-F57BD7D0F5E9

Q37019841-D9575FAC-E0F8-496B-BCBD-FBE45AD0569C

Q37019841-D9D33B02-CEE5-466B-86D9-3CC9AA212586

P577

Q37019841-A7E06764-14B9-4137-AEBA-1F13E32F6ADC

P698

Q37019841-DBC9A3E6-4CA5-4772-B909-040E8578A537

P932

Q37019841-CE13D0AE-CCBC-46E5-8A68-EEE686E2DB87

P356

1078-0432.CCR-09-2871

P1433

Clinical Cancer Research

P1476

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

@en

P2093

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

James A Eastham

http://www.w3.org/2001/XMLSchema#string

Jasmine Bhatia

http://www.w3.org/2001/XMLSchema#string

Kinjal Vora

http://www.w3.org/2001/XMLSchema#string

Lisa Balistreri

http://www.w3.org/2001/XMLSchema#string

Mia M Gaudet

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

Prodipto Pal

http://www.w3.org/2001/XMLSchema#string

Robert J Klein

http://www.w3.org/2001/XMLSchema#string

Samson W Fine

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.

Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.

Cancer risks in BRCA2 mutation carriers.

Cancer Incidence in BRCA1 mutation carriers.

P304

2115-2121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2871

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Morris

David J Gallagher

Tomas Kirchhoff

Michael J Zelefsky

P577

2010-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20215531

http://www.w3.org/2001/XMLSchema#string

P932

3713614

http://www.w3.org/2001/XMLSchema#string